Literature DB >> 21071344

Immunohistochemical detection of dopamine D2 receptors in human pituitary adenomas.

Marek Pawlikowski1.   

Abstract

Thirty one pituitary adenomas and 3 samples of peritumoral anterior pituitary tissue were immunostained with an antibody raised against dopamine D2 receptor protein. The positive reactions were found in cell cytoplasm, a subpopulation of cell nuclei and the intratumoral blood vessels walls. As expected, the positive immunostaining was shown in cytoplasm and/or cell nuclei of all examined prolactinomas (7/7). In acromegaly the positive D2 staining occurred in 5/7 samples, in gonadotropinomas in 6/8 and in plurihormonal adenomas 2/4. The lowest expression was observed in corticotropinomas (1/5). These findings corroborate with the well known efficacy of D2 agonists in the treatment of prolactinomas and somatotropinomas, and support the rationale of the therapeutic trials with these compounds in gonadotropinomas. Moreover, the presence of D2 receptors in intratumoral blood vessels walls constitutes the possibility of the anti-angiogenic action of D2 agonists in pituitary adenomas.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21071344     DOI: 10.2478/v10042-010-0031-1

Source DB:  PubMed          Journal:  Folia Histochem Cytobiol        ISSN: 0239-8508            Impact factor:   1.698


  4 in total

1.  Dopamine agonist-responsive Cushing's disease.

Authors:  Gurpreet Anand; Andrea Bink; Felix Beuschlein; Christoph Schmid
Journal:  BMJ Case Rep       Date:  2019-02-13

Review 2.  Dopamine Agonists in the Management of Non-Functioning Pituitary Adenomas.

Authors:  C Capatina; C Poiana
Journal:  Acta Endocrinol (Buchar)       Date:  2021 Jul-Sep       Impact factor: 0.877

Review 3.  The dopaminergic control of Cushing's syndrome.

Authors:  R Pivonello; C Pivonello; C Simeoli; M C De Martino; A Colao
Journal:  J Endocrinol Invest       Date:  2022-04-23       Impact factor: 5.467

Review 4.  Dopamine Agonists for Pituitary Adenomas.

Authors:  Odelia Cooper; Yona Greenman
Journal:  Front Endocrinol (Lausanne)       Date:  2018-08-21       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.